India Unit Of Sanofi-Aventis Told By WHO 5-Disease Vaccine Has Problem
This article was originally published in PharmAsia News
Executive SummaryThe Indian subsidiary of French drug maker Sanofi-Aventis has been told by the United Nations it was suspending purchase and use of the Shan5 vaccine for five diseases, including tetanus
You may also be interested in...
WHO's Product Recall Order For Shantha Biotech's Vaccine Puts Sanofi Aventis In Crisis Management Mode; Vows To Resume Supplies By End Of 2010
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).